Anadys Pharmaceuticals Inc. (Nasdaq: ANDS) reported upbeat results from a midstage clinical trial of its hepatitis C treatment ANA598 but the stock price dropped 34 cents to close at $2.60.
Upbeat Clinical Trial Results For Anadys
December 17, 2009 at 18:32 PM EST
